Literature DB >> 14560966

Retroviral oncogenes and TOR.

M Aoki1, P K Vogt.   

Abstract

Retroviruses have recruited the catalytic subunit of PI 3-kinase and its downstream target, Akt, as oncogenes. These viruses cause tumors in animals and induce oncogenic transformation in cell culture. The oncogenicity of these viruses is specifically inhibited by rapamycin; retroviruses carrying other oncogenes are insensitive to this macrolide antibiotic. Rapamycin is an inhibitor of the TOR (target of rapamycin) kinase whose downstream targets include p70 S6 kinase and the negative regulator of translation initiation 4E-BP. Emerging evidence suggests that the TOR signals transmitted to the translational machinery are essential for oncogenic transformation by the PI 3-kinase pathway.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14560966     DOI: 10.1007/978-3-642-18930-2_19

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  5 in total

1.  Proteasomal degradation of the FoxO1 transcriptional regulator in cells transformed by the P3k and Akt oncoproteins.

Authors:  Masahiro Aoki; Hao Jiang; Peter K Vogt
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-01       Impact factor: 11.205

2.  A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma.

Authors:  Qi-Wen Fan; Zachary A Knight; David D Goldenberg; Wei Yu; Keith E Mostov; David Stokoe; Kevan M Shokat; William A Weiss
Journal:  Cancer Cell       Date:  2006-05       Impact factor: 31.743

3.  Phosphorylation of eIF4E by Mnk-1 enhances HSV-1 translation and replication in quiescent cells.

Authors:  Derek Walsh; Ian Mohr
Journal:  Genes Dev       Date:  2004-03-15       Impact factor: 11.361

4.  Constitutively active Rheb induces oncogenic transformation.

Authors:  H Jiang; P K Vogt
Journal:  Oncogene       Date:  2008-06-02       Impact factor: 9.867

Review 5.  Interactions between PTEN and receptor tyrosine kinase pathways and their implications for glioma therapy.

Authors:  Roger Abounader
Journal:  Expert Rev Anticancer Ther       Date:  2009-02       Impact factor: 4.512

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.